Core Insights - Kirby McInerney LLP is investigating potential claims against Septerna, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3] - On February 18, 2025, Septerna announced the discontinuation of its Phase 1 clinical trial for SEP-786 due to two severe cases of elevated unconjugated bilirubin, leading to a significant drop in share price [3] Company Developments - Septerna decided to halt the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism treatment [3] - The decision was prompted by the observation of two unexpected severe (Grade 3) cases of elevated unconjugated bilirubin without corresponding increases in liver enzyme levels [3] - Following the announcement, Septerna's share price fell by 12.96 on February 14, 2025, to $6.87 on February 18, 2025 [3]
Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors